Hyperreflective foci as an independent visual outcome predictor in macular EDEMA due to retinal vascular diseases treated with intravitreal dexamethasone or ranibizumab

Retina

Volumn 36, Issue 12, 2016, Pages 2319-2328

  Chatziralli, Irini P ^a   Sergentanis, Theodoros N ^b   Sivaprasad, Sobha ^a,c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ATHENS   (Greece)

^c Moorfields NIHR Ophthalmology Biomedical Research Centre   (United Kingdom)

Author keywords

branch retinal vein occlusion dexamethasone; diabetic macular edema; hyperreflective foci; predictor; ranibizumab

Indexed keywords

DEXAMETHASONE; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID;

AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; CYST; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INTRAVITREAL IMPLANT; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETINA DISEASE; RETINA FOVEA; RETROSPECTIVE STUDY; SLIT LAMP MICROSCOPY; SMOKING HABIT; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; SUSTAINED DRUG RELEASE; VISION; VISUAL ACUITY; COMPLICATION; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; RETINA VEIN OCCLUSION; RISK FACTOR;

AGED; ANGIOGENESIS INHIBITORS; DEXAMETHASONE; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84973279458     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000001070     Document Type: Article

References (36)

1. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35:556-564.
2. Aiello LP; DCCT/EDIC Research Group. Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014;37:17-23.
3. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313-319.
4. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32.
5. Ehrlich R, Harris A, Ciulla TA, et al. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol 2010;88:279-291.
6. Ascaso FJ, Huerva V, Grzybowski A. The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases. Mediators Inflamm 2014;2014:432685.
7. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331: 1480-1487.
8. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 2011;152:686-694.
9. Ach T, Hoeh AE, Schaal KB, et al. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010;248:155-159.
10. Daien V, Navarre S, Fesler P, et al. Visual acuity outcome and predictive factors after bevacizumab for central retinal vein occlusion. Eur J Ophthalmol 2012;22:1013-1018.
11. Chhablani JK, Kim JS, Cheng L, et al. External limiting membrane as a predictor of visual improvement in diabetic macular edema after pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol 2012;250:1415-1420.
12. Mohamed S, Leung GM, Chan CK, et al. Factors associated with variability in response of diabetic macular oedema after intravitreal triamcinolone. Clin Exp Ophthalmol 2009;37: 602-608.
13. Wolf S, Wolf-Schnurrbusch U. Spectral-domain optical coherence tomography use in macular diseases: A review. Ophthalmologica 2010;224:333-340.
14. Coscas G, Coscas F, Vismara S, et al. Spectral Domain OCT in age-related macular degeneration: preliminary results with Spectralis HRA-OCT. J Fr Ophtalmol 2008;31:353-361.
15. Coscas G, Coscas F, Vismara S, et al. Clinical features and natural history of AMD. In: Coscas G, Coscas F, Vismara S, et al, eds. Optical Coherence Tomography in Age-related Macular Degeneration. Heidelberg, Germany, Springer; 2009:171-174.
16. Bolz M, Schmidt-Erfurth U, Deak G, et al; Diabetic Retinopathy Research Group Vienna. Optical coherence tomographic hyperreflective foci: A morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology 2009;116:914-920.
17. Framme C, Wolf S, Wolf-Schnurrbusch U. Small dense particles in the retina observable by spectral-domain optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci 2010;51:5965-5969.
18. Folgar FA, Chow JH, Farsiu S, et al. Spatial correlation between hyperpigmentary changes on color fundus photography and hyperreflective foci on SDOCT in intermediate AMD. Invest Ophthalmol Vis Sci 2012;53:4626-4633.
19. Coscas G, De Benedetto U, Coscas F, et al. Hyperreflective dots: A new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica 2013;229:32-37.
20. Christenbury JG, Folgar FA, O'Connell RV, et al; Age-related Eye Disease Study 2 Ancillary Spectral Domain Optical Coherence Tomography Study Group. Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. Ophthalmology 2013;120:1038-1045.
21. Vujosevic S, Bini S, Midena G, et al. Hyperreflective intraretinal spots in diabetics without and with nonproliferative diabetic retinopathy: An in vivo study using spectral domain OCT. J Diabetes Res 2013;2013:491835.
22. Nishijima K, Murakami T, Hirashima T, et al. Hyperreflective foci in outer retina predictive of photoreceptor damage and poor vision after vitrectomy for diabetic macular edema. Retina 2014;34:732-740.
23. Uji A, Murakami T, Nishijima K, et al. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am J Ophthalmol 2012;153:710-717.
24. Framme C, Schweizer P, Imesch M, et al. Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2012;53:5814-5818.
25. De Benedetto U, Sacconi R, Pierro L, et al. Optical coherence tomographic hyperreflective foci in early stages of diabetic retinopathy. Retina 2015;35:449-453.
26. Ogino K, Murakami T, Tsujikawa A, et al. Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion. Retina 2012;32:77-85.
27. Kang JW, Lee H, Chung H, Kim HC. Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after intravitreal bevacizumab for macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2014;252:1413-1421.
28. Roberts P, Mittermueller TJ, Montuoro A, et al. A quantitative approach to identify morphological features relevant for visual function in ranibizumab therapy of neovascular AMD. Invest Ophthalmol Vis Sci 2014;55:6623-6630.
29. Murakami T, Yoshimura N. Structural changes in individual retinal layers in diabetic macular edema. J Diabetes Res 2013; 2013:920713.
30. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146.
31. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:633. e1-4.
32. Ota M, Tsujikawa A, Murakami T, et al. Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. Br J Ophthalmol 2007;91: 1644-1649.
33. Murakami T, Tsujikawa A, Ohta M, et al. Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator. Am J Ophthalmol 2007;143:171-173.
34. Maheshwary AS, Oster SF, Yuson RM, et al. The association between percent disruption of the photoreceptor inner segmentouter segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol 2010;150:63-67.
35. Forooghian F, Stetson PF, Meyer SA, et al. Relationship between photoreceptor outer segment length and visual acuity in diabetic macular edema. Retina 2010;30:63-70.
36. Tsujikawa A, Sakamoto A, Ota M, et al. Serous retinal detachment associated with retinal vein occlusion. Am J Ophthalmol 2010;149:291-301.